Catalog No.
FHB86930
Species reactivity
Human
Host species
Mouse
Isotype
IgG2a, kappa
Clonality
Monoclonal
Conjugation
Unconjugated
Target
Epidermal growth factor receptor, 2.7.10.1, Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, EGFR, ERBB, ERBB1, HER1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00533
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.09% Sodium azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
11F8
Effects of Ganoderma spent substrate containing with polysaccharides and triterpenoids on the growth performance, antioxidant capacity and immunity level of chickens., PMID:40532998
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Comparison of Intrapatient Variability of IR-Tacrolimus Versus LCP-Tacrolimus in a Cohort of Lung Transplant Recipients., PMID:40525559
Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study., PMID:40524516
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation., PMID:40523897
Precision medicine approaches to CNS metastatic disease., PMID:40518193
Engineered MAP30ER: A plant toxin-derived platform for EGFR-Targeted delivery of protein and chemotherapeutic payloads., PMID:40517671
Nanobodies targeting EGFR provide insight into conformations stabilized by glioblastoma mutations., PMID:40516870
A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC., PMID:40516821
Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study., PMID:40514709
Structural insights into the activation and inhibition of the ADAM17-iRhom2 complex., PMID:40512800
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type., PMID:40512776
LiGeR-HN phase III trials of petosemtamab + pembrolizumab and petosemtamab monotherapy in recurrent or metastatic HNSCC., PMID:40511820
Unraveling Botulinum Neurotoxin A Light-Chain-Induced Signaling Pathways: A Phosphoproteomic Analysis in a Controlled Cellular Model., PMID:40507977
Facial Skin With Conspicuous Enlarged Pores Closely Related to Severity of Facial Acneiform Rash and Therapeutic Effects of EGFR Inhibitors in RAS Wild-Type Metastatic Colorectal Cancer: Ancillary Analysis of FAEISS Study (NCCH1512)., PMID:40503645
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection., PMID:40503012
Advances in cancer research on FUT8Molecular mechanisms and clinical applications., PMID:40497775
Exploring cellular plasticity and resistance mechanisms in lung cancer: Innovations and emerging therapies., PMID:40496071
Effects of concurrent HER2-directed therapy on development of cerebral radionecrosis after stereotactic radiotherapy: a systematic review., PMID:40493045
Predictive power of tertiary lymphoid structure for prognosis and neoadjuvant chemotherapy response in HER2-positive breast cancer., PMID:40489875
An Advanced IVB Lung Adenocarcinoma Patient With KRAS Mutations, Benefited From Camrelizumab Combined With Anti-Angiogenic Agents for Therapy: A Case Report., PMID:40488279
Epidermal Growth Factor Receptor (EGFR) Downregulation by Cetuximab in Salivary Duct Carcinoma: A Case Report., PMID:40486390
Pretransplant natural antibody levels identify a subset of deceased donor kidney transplant recipients that benefit from infliximab induction., PMID:40484132
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers., PMID:40480221
Aptamers as therapeutic targets: prospects and progress in the treatment of cancers., PMID:40479828
Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial., PMID:40473437
Advances and Future Perspectives of HER2 Mutations in Non-Small Lung Cancer (NSCLC), Especially in China., PMID:40472040
Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors., PMID:40469307
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysis., PMID:40468999
Successful Treatment of HER2 V659E Mutation-Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report., PMID:40468744
HS-10375, a selective EGFR C797S tyrosine kinase inhibitor, in advanced non-small cell lung cancer., PMID:40468352
Retrospective stratified analysis of resistance mechanisms to anti-EGFR therapy in mCRC using tumor tissue samples., PMID:40467730
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib., PMID:40466026
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer., PMID:40464376
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417
Mechanisms of resistance to antibody-drug conjugates in cancers., PMID:40460510
First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report., PMID:40460045
Targeting endothelial growth factor receptor in thyroid cancer: current concepts and future directions., PMID:40457134
Epidermal growth factor receptor specific immunotherapy for SHH medulloblastoma tested in an in vitro blood-brain barrier-model., PMID:40456204
Cutaneous adverse effects of combination epidermal growth factor receptor inhibitor and immune checkpoint inhibitor cancer therapy., PMID:40455297
T-cell activation enhances anti-HER2-mediated antibody-dependent cellular cytotoxicity in gastric cancer., PMID:40455140
Tocilizumab-Based Treatment of Microvascular Inflammation in Kidney Transplant Recipients: A Retrospective Study., PMID:40454296
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models., PMID:40452841
Contribution of Anti-type IV Collagen Antibodies From Kidney Basement Membrane to Increased Level of Urinary Immunoglobulin G in Nephritis Patients: A Comparison of Nephritic and Healthy Urine., PMID:40452732
Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations., PMID:40448190
Intracranial and systemic progression on amivantamab in platinum-treated epidermal growth factor receptor exon 20 insertion-mutated advanced non-small cell lung cancer., PMID:40446773
Solution structure and synaptic analyses reveal determinants of bispecific T cell engager potency., PMID:40445758
[Research progress on the mechanisms of resistance to cetuximab targeted therapy in head and neck squamous cell carcinoma]., PMID:40443385
Safety and efficacy of sirolimus combined with cyclosporine in primary membranous nephropathy: a randomized controlled trial., PMID:40442735
For research use only. Not for human or drug use.
